India Brugada Syndrome Market Analysis

India Brugada Syndrome Market Executive Summary

The India Brugada Syndrome Market is at around $21.8 Mn in 2023 and is projected to reach $44.7 Mn in 2030, exhibiting a CAGR of 10.8% during the forecast period.

Brugada syndrome is a rare, but potentially threatening, genetic condition that causes abnormal electrical activity in the heart, leading to an increased risk of sudden cardiac death. People with Brugada syndrome have an increased risk of irregular heart rhythms beginning in the lower chambers of the heart, i.e., the ventricles. Common signs and symptoms associated with Brugada Syndrome include dizziness, fainting, gasping and laboured breathing, particularly at night, irregular heartbeats or palpitations, extremely fast and chaotic heartbeat, and seizures. The risk factors for Brugada syndrome include family history of Brugada syndrome, being male, race, and fever.

The India Brugada Syndrome Market is driven by significant factors such as growing prevalence of cardiovascular diseases, advancements in genetic testing, and aging population. However, high cost of treatment, side effects and complications of treatment, and limited awareness restrict the growth and potential of the market.

The major players of the India Brugada Syndrome Market are Intas, Sun Pharmaceuticals, Cipla, Divi's Lab, Dr. Reddy's Laboratories, and Zydus Lifesciences, among others.

Market Dynamics

Market Growth Drivers

Growing Prevalence of Cardiovascular Diseases: The prevalence of diagnosed CVDs was 29.4% for older adults age 45 and above in India in 2021. The rise in cardiovascular disease prevalence in India is a major factor driving the Brugada syndrome market. As overall cardiac health worsens, there is a greater emphasis on awareness and screening for heart conditions, which can indirectly aid in identifying Brugada syndrome, a rare but serious arrhythmia. This intensified focus on cardiovascular health will increase the number of Brugada syndrome cases, boosting the demand for diagnostic tools, treatments, and patient management services, and thereby stimulating market growth.

Advancements in Genetic Testing: Advancements in genetic testing in India are significantly boosting the Brugada syndrome market. The growing accessibility and affordability of these tests are allowing for earlier and more precise diagnoses, which leads to timely interventions and better patient outcomes. As genetic testing becomes more widespread, it is identifying more cases of Brugada syndrome, thus expanding the market for diagnostic tools, treatments, and patient management services. Additionally, progress in genetic research is deepening the understanding of the disease's mechanisms, enabling the development of targeted therapies and personalized treatment approaches, leading to overall market growth.

Aging Population: The population aged 60 and above in India is 153 Mn which is more susceptible to chronic cardiac conditions. India's aging population is driving increased demand for Brugada syndrome market. As people live longer, the risk of heart conditions like Brugada syndrome grows. This means a larger patient base needing early detection, treatment, and ongoing care. Consequently, the market for diagnostic tools, therapies, and patient monitoring devices for Brugada syndrome is expanding.

Market Restraints

High Cost of Treatment: In India, the high expense of Brugada syndrome treatments presents a major obstacle to market growth. The advanced diagnostic procedures, specialized medications, and implantable devices needed to manage the condition are too costly for many people. This financial strain restricts access to treatment, leading to delays in diagnosis, inadequate care, and potentially higher mortality rates. As a result, the steep cost of treatment impedes market expansion by limiting patient affordability and reducing the overall demand for Brugada syndrome-related products and services.

Side Effects and Complications of Treatments: Treatments for Brugada syndrome, although crucial for preventing sudden cardiac death, has certain side effects and complications. Implantable cardioverter-defibrillators (ICDs), a primary treatment, leads to discomfort, infections, or issues related to the device. Antiarrhythmic medications can cause side effects such as nausea, dizziness, or elevated heart rate. Radiofrequency ablation, another treatment method, carries risks including arrhythmias, heart damage, and other potential complications. These factors can lead to the overall decreased growth of the Brugada Syndrome Market.

Limited Awareness: In India, limited awareness of Brugada syndrome among the general public, healthcare providers, and patients poses a major obstacle to market growth. The insufficient knowledge about the condition’s symptoms, risk factors, and treatment options results in delayed diagnoses, missed prevention opportunities, and less effective patient management. This lack of awareness diminishes the demand for diagnostic tests, therapeutic interventions, and patient support services, thereby affecting the overall growth of the Brugada syndrome market.

Regulatory Landscape and Reimbursement Scenario

In India, the primary regulatory body for pharmaceutical sector is the Central Drugs Standard Control Organization (CDSCO) and the Drug Controller General of India (DCGI) is the key official within the CDSCO. The CDSCO consistently works to achieve transparency, accountability, and standardization in its services to guarantee the safety, effectiveness, and quality of medical products that are produced, imported, and distributed throughout the nation. The Drugs & Cosmetics Act, 1940 and Rules 1945 lays out the foundation for ensuring the safety, rights and well-being of patients by regulating the manufacturing, import, sale, and distribution of drugs and cosmetics.

Under this act, CDSCO is responsible for granting license for approved drugs, conducting clinical trials, setting standards for drugs, monitoring the quality of drugs imported into the nation, and coordinating the efforts of State Drug Control Organizations by offering professional advice in an effort to standardize the enforcement of the D&C Act.

India's healthcare reimbursement scenario is complex and evolving, with both public and private players involved. Ayushman Bharat Pradhan Mantri Jan Arogya Yojana is a national public health insurance scheme of the Government of India that aims to provide free access to health insurance coverage for low-income earners in the country. These programs offer cashless or payment benefits for certain illness-related hospital stays in affiliated hospitals. Certain demographics, such as government employees, are eligible for social health insurance programs in several states. Private insurance firms’ voluntary health insurance programs are becoming more popular. Reimbursement decisions are made according to the specific plan purchased and cover surgery, hospital stays, and occasionally, prescription drugs.

Competitive Landscape

Key Players

Here are some of the major key players in the India Brugada Syndrome Market:

• Intas
• Sun Pharmaceuticals
• Cipla
• Divi's Lab
• Dr. Reddy's Laboratories
• Zydus Lifesciences
• Mankind Pharma
• Ajanta Pharma
• Medtronic
• Siemens Healthineers